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211Transcatheter aortic valve replacement (TAVR) gained Con-
formité Européenne (CE) mark approval in 2007, and the
number of patients undergoing TAVR in Europe has
increased exponentially in subsequent years. Despite the
encouraging results from randomized, controlled trials and
registries (1–4), there is anecdotal evidence that the use of
TAVR varies markedly across European nations.See page 220
TAVR = transcatheter aortic
valve replacementDisparate adoption of medical technology is pervasive and
results in inequitable patient access (5). Adoption kinetics
of a novel medical technology such as TAVR and the
factors inﬂuencing these variables have not been previously
described. Regional differences in TAVR adoption are likely
to have emerged because of variations in social, regulatory,
economic, and political circumstances, as well as disease
prevalence and longevity. This information may be of interest
to patients, healthcare professionals, regulatory authorities,
the medical device industry, and healthcare payers. In addi-
tion, these data may have implications for healthcare resource
allocation, service development planning, assessment of
equitable patient access, and physician training.
We sought to address this information gap by examining
the trends in both the number of TAVR implants and
number of centers across 11 European countries since CE
mark approval. In addition, we investigated factors that may
inﬂuence the heterogeneous adoption of this novel tech-
nology across nations.Methods
Data sourcing. We investigated TAVR use in 11 European
countries: Germany, France, Italy, United Kingdom (including
Northern Ireland), Spain, the Netherlands, Switzerland,
Belgium, Portugal, Denmark, and Ireland. Data were collected
from 2 distinct sources. First we identiﬁed data from published
national registries and large databases in countries in which
reimbursement is linked to registry inclusion (3,4,6–8). Lead
physicians from each nation submitted data from national
registries regarding the annual number of patients treated with
TAVRand the annual number of implanting centers from2007
to 2011. Lead physicians take responsibility for the integrity of
the data (Online Table 1).
Secondly, we present data from BIBAMedTech (London,
United Kingdom), a cardiovascular market analysis group
tracking TAVR use since mid-2009. These data were gath-
ered through speciﬁcally designed questionnaires and pre-
arranged telephone interviews with an extensive research
panel comprising interventional cardiologists, cardiac
surgeons, and administrators from a large number of
TAVR centers throughout Europe. National implant esti-
mates were extrapolated using an algorithm that incorpo-
rated the following variables: device pricing, national
guidelines, national reimbursement policies, portfolio, spread,and trend. This ﬁnal data set was
cross-referenced with published
registries.
Nation-speciﬁc data were com-
bined with European Union–
derived year-end population esti-
mates (9) to calculate the: 1) annual
and cumulative number ofTAVRs
performed in each nation; 2)
annual number ofTAVR implants
per million population and TAVR implants per million pop-
ulation of age 75 years; 3) annual and cumulative number of
TAVR centers in each nation; 4) number of TAVR centers per
million population; and 5) mean number of TAVR implants
per center for each nation.
TAVR penetration. The penetration rate of a therapy is a
descriptor of the use of that therapy among eligible patients.
Thus, TAVR penetration in each nation was determined as
a measure of actual TAVR use relative to potential use. The
numerator for calculating penetration was the number of
living TAVR recipients at year end in each country. This
was calculated as the sum of patients receiving TAVR in that
calendar year and the number of living TAVR recipients
from previous years. Annual mortality rates at 1, 2, 3, and
4 years following TAVR were assumed to be 24%, 33%, 49%,
and 57%, respectively (10). The denominator was an estimate
of the prevalence of patients with symptomatic severe aortic
stenosis at high or excessive surgical risk that could poten-
tially be treated with TAVR (11). Brieﬂy, the proportion of
elderly inhabitants of each country of age 75 years with
severe aortic stenosis (3.4%) was determined by a random-
effects meta-analysis. Among these patients, 75.6% were
estimated to be symptomatic, 40.5% were deemed to be
inoperable due to excessive surgical risk, and 5.2% were
determined to be at high operative risk among the patients
who received surgical aortic valve replacement (Society of
Thoracic Surgeons risk of mortality 10%). Finally, 40.3%
of inoperable patients and 80.0% of the high-risk patients
were deemed to be potential TAVR candidates.
Economic indexes. National economic indexes and health-
care parameters for 2011 were obtained from European
Union and Organisation for Economic Co-operation and
Development databases (12). To establish economic factors
associated with TAVR use, we correlated the number of
TAVR implants per million population (age 75 years) to
the volume indexed gross domestic product (GDP) per
capita in purchasing power standards. GDP per capita in
purchasing power standards is obtained by converting GDP
per capita to a ﬁctive currency using purchasing power pari-
ties that eliminate differences in currency and price levels
between countries, thereby allowing meaningful volume
comparisons of GDP. In addition, we correlated the number
of TAVR implants per million population (age 75 years)
with the percentage of GDP spent on health care and the
purchasing power parities–adjusted total healthcare expen-
diture per capita (U.S.$). In Europe, health care is funded
AB
Figure 1 TAVR Adoption in Europe
(A) Cumulative transcatheter aortic value replacement (TAVR) implants in
11 Western European nations between 2007 and 2011. (B) TAVR implants
per annum and percentage annual increase (solid line).
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212either by taxation or by social insurance institutions, which
are largely outside the commercial marketplace. We classiﬁed
healthcare ﬁnancing in each country according to the prin-
cipal source of funding and compared TAVR use between
these systems.Table 1 TAVR Implants in Each Nation
TAVR Implants per Annum, %
2007 2008 2009
Germany 157 921 (487) 2,566 (179)
France 58 82 (41) 320 (290)
Italy 71 450 (534) 1,138 (153)
United Kingdom 66 295 (347) 561 (90)
Spain 12 151 (1,158) 426 (182)
the Netherlands* 40 123 (208) 226 (84)
Switzerland 18 127 (606) 277 (118)
Belgium* 10 100 (900) 163 (63)
Portugal 4 13 (225) 52 (300)
Denmark 9 81 (800) 126 (56)
Ireland 0 12 61 (408)
Total (% increase) 445 2,355 (429) 5,916 (151)
Values are n (%). *Excludes 1 low-implant volume center (<30 TAVR implants per annum) in both the N
TAVR ¼ transcatheter aortic valve replacement.TAVR reimbursement. Medical device reimbursement in
Europe is inconsistent because healthcare regulators with
diverse policies dictate the method of reimbursement
(12). We divided existing 2011 TAVR reimbursement into
2 categories and compared TAVR use between these
schemes: 1) “TAVR-speciﬁc” systems, in which TAVR
is completely reimbursed via a therapy-speciﬁc national
diagnosis-related group (DRG) tariff; and 2) “constrained”
systems, in which TAVR reimbursement is only partially
funded by an existing national DRG tariff or the cost is
borne by a local healthcare trust or hospital budget.
Statistics. Continuous variables are presented as mean SD
or median with interquartile range according to distribution.
Normally distributed variables were compared with the
Student t test and nonnormally distributed variables compared
with the Wilcoxon rank-sum test. Categorical variables are
presented as numbers and percentages. Bland-Altman plots
were used to graphically compare the 2 sources of TAVR
implant data. Correlation between economic indexes and
TAVR implants per million population (age 75 years) was
assessed using the Pearson or Spearman correlation according
to distribution. A probability value <0.05 was considered
to indicate statistical signiﬁcance. Analyses were performed
using SPSS version 17.0 (SPSS Inc., Chicago, Illinois).
Results
Data sourcing. With the exception of 1 small center (<30
TAVR implants per annum) in both the Netherlands and
Belgium, complete data were available from the 11 study
nations. Herein, we report the results from the national
databases which include TAVR implant data since CE mark
approval in 2007. The BIBA MedTech data set includes
data from 2009 to 2011 and is presented in the Online
Appendix.
Implantation rates. Between January 2007 and December
2011, 34,317 patients underwent TAVR in the 11 study
nations (Fig. 1A). Almost half of all implants were performed
in Germany (45.9%), with Italy (14.9%) and France (12.9%)increase
Cumulative
TAVR
Cumulative
TAVR, %2010 2011
4,859 (89) 7,252 (49) 15,755 45.9
1,523 (376) 2,447 (61) 4,430 12.9
1,581 (39) 1,879 (19) 5,119 14.9
778 (39) 1,037 (33) 2,737 8.0
655 (54) 770 (18) 2,014 5.9
329 (46) 438 (33) 1,156 3.4
382 (38) 501 (31) 1,305 3.8
257 (58) 289 (12) 819 2.4
67 (29) 65 (-3) 201 0.6
190 (51) 239 (26) 645 1.9
34 (44) 29 (15) 136 0.4
10,655 (81) 14,946 (40) 34,317 100
etherlands and Belgium.
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213the next most frequent implanters (Table 1). Ireland
accounted for the smallest proportion of implants (0.4%).
In 2011, the highest annual increases in procedural volume
were observed in France (61%) and Germany (49%), whereas
Ireland (15%) and Portugal (3%) were the only nations to
experience declines. The annual number of implants increased
33-fold from 455 in 2007 to 14,946 in 2011 (Fig. 1B).
Although the annual procedural volume growth rate decreased
from 429% in 2008 to 40% in 2011, it remained positive.
We observed a wide variation in the number of TAVR
implants per million population (Figs. 2A and 2B). Germany
(88.7) and Portugal (6.1) accounted for the highest and
lowest number of TAVR implants per million populationA
B
Figure 2
TAVR Implants per Million Population
in the Study Nations
TAVR implant dynamics in the study nations between 2007 and 2011. (A) TAVR
implants per million population. (B) TAVR implants per million population age 75
years. Broken line represents mean. Abbreviation as in Figure 1.
B
C
Figure 3 TAVR Centers in Europe
(A) Cumulative TAVR centers in 11 Western European nations from 2007 to 2011.
(B) TAVR centers per million population in 2011. (C) Mean number of TAVR
implants per center in each nation in 2011. Broken line represents mean.
Abbreviation as in Figure 1.
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214in 2011, respectively. Among the 11 study nations, the
mean number of TAVR implants per million population was
32.9  24.9 and the mean number of TAVR implants per
million population age 75 years was 398  283.
Implanting centers. The number of centers performing
TAVR increased approximately 9-fold from 37 in 2007 to
342 in 2011 (Fig. 3A). In 2011, Germany (90) and Italy (87)
had the highest number of TAVR centers, whereas Portugal,
Denmark, and Ireland (3 each) had the lowest (Table 2).
Belgium had the highest number of TAVR centers per
million population (2.1) and Portugal (0.3) the lowest
(Fig. 3B). On average, there were 0.9  0.6 TAVR centers
per million population. These numbers led to an average of
41  28 TAVR implants per center in 2011, with estimates
in individual countries ranging from 10 in Ireland to 89 in
Germany (Fig. 3C). On account of the high number of
TAVR centers per million population, Belgium had the
second lowest number of TAVR implants per center (13).
TAVR penetration. In 2011, we estimated that there were
28,400 living TAVR recipients and 158,371 potential TAVR
candidates in the 11 study nations (Table 3). Thus, the
calculated weighted average TAVR penetration rate in 2011
was 17.9%. The estimated collective and nation-speciﬁc
TAVR penetration rates are presented in Figures 4A and 4B.
Germany (36.2%) and Switzerland (34.5%) had the highest
TAVR penetration rates; Portugal (3.4%) and Spain (8.4%)
had the lowest penetration rates.
Economic indexes. We assessed the association between
several economic indexes and TAVR use (Table 4). The
volume-indexed GDP per capita, which is considered to be
a reliable indicator of a country’s standard of living, was not
associated with TAVR use (r ¼ 0.53; p¼ 0.10) (Fig. 5A). In
contrast, a signiﬁcant linear correlation was found between
the number of TAVR implants per million population
(age 75 years) and healthcare spending as a percentage
of GDP (r ¼ 0.68; p ¼ 0.025) (Fig. 5B) and healthcare
spending per capita (r ¼ 0.80; p ¼ 0.005) (Fig. 5C). WeTable 2 Implant Centers
Cumulative TAVR Centers
2007 2008 2009 2010 2
Germany 6 36 61 80
France 6 12 16 33
Italy 8 21 50 75
United Kingdom 6 19 26 31
Spain 2 10 20 39
the Netherlands 3 6 7 7
Switzerland 1 7 8 11
Belgium 2 7 13 20
Portugal 1 2 3 3
Denmark 2 3 3 3
Ireland 0 1 3 3
Total 37 124 210 305 3
Values are n or mean  SD, unless otherwise indicated.
Abbreviation as in Table 1.also found an association between the principal source of
healthcare funding and the number of TAVR implants per
million population (Fig. 5D). Although not statistically
signiﬁcant, there was a trend toward increased TAVR use in
those nations in which healthcare was funded principally
by social insurance (Germany, France, the Netherlands,
Switzerland, and Belgium) than those principally funded by
taxation (Italy, United Kingdom, Spain, Portugal, Denmark,
and Ireland) (571  290 vs. 252  192 implants per million
population age 75 years; p ¼ 0.056).
TAVR reimbursement. TAVR reimbursement strategies
across the study nations were heterogeneous (Fig. 6, Table 4).
TAVR-speciﬁc national DRG-based reimbursement occurs
in Germany, France, Switzerland, and Denmark. Con-
strained reimbursement systems were noted for the United
Kingdom, Spain, the Netherlands, Belgium, Portugal, and
Ireland, where the cost of TAVR is borne by a local healthcare
trust (United Kingdom) or by the hospital budget. Reim-
bursement systems evolved over the course of the study. For
example, a TAVR-speciﬁc DRGwas introduced in Germany
in January 2008 as opposed to France, where it was intro-
duced in December 2009.
We investigated the association between reimbursement
system and both TAVR use (implants per million population
age75 years) and the number of TAVR implants per center.
Italy was excluded from the analysis because reimbursement
strategies varied across provinces. TAVR-speciﬁc reim-
bursement systems were associated with a 3.3-fold higher
number of TAVR implants per million population
(age 75 years) than constrained systems (698  232 vs.
213 112; p¼ 0.002) (Fig. 5E). Furthermore, TAVR-speciﬁc
reimbursement systems were associated with 2.5 times more
TAVR implants per center than constrained systems (69 18
vs. 26  20 implants per center; p ¼ 0.008) (Fig. 5F).
Comparison between registry and BIBA data sets. The
correlation between national registry and BIBA MedTech
data sets for TAVR implant numbers is presented in aTAVR Centers,
2011, %
TAVR Centers
per Million
Population, 2011
TAVR Implants
per Center, 2011011
90 26.3 1.1 81
33 9.6 0.5 74
87 25.4 1.4 22
33 9.6 0.5 31
48 14.0 1.0 16
7 2.0 0.4 63
12 3.5 1.5 42
23 6.7 2.1 13
3 0.9 0.3 22
3 0.9 0.5 80
3 0.9 0.7 10
42 100 0.9  0.6 41  28
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215Bland-Altman plot (Online Fig. 1). There was satisfactory
agreement between the 2 sources of information, and both
provided similar results and conclusions (Online Figs. 2 to 6,
Tables 2 to 4).
Discussion
This study described the adoption of TAVR in 11 Western
European nations since the 2007 CE mark approval of
the Edwards Sapien (Edwards Lifesciences Inc., Irvine,
California) and Medtronic CoreValve (Medtronic Inc.,
Minneapolis, Minnesota) systems. The main ﬁndings are:
1) more than 34,000 patients received TAVR between 2007
and 2011; 2) there is substantial variation in the adoption of
TAVR across nations; 3) there is disparity in the annual
number of TAVR implants per center across nations (mean
41  28); 4) TAVR remains greatly underutilized, with
an estimated weighted penetration rate of 17.9%; and
5) economic and reimbursement indexes may help explain
the variability in TAVR adoption across nations.
We found considerable variation in TAVR use across
nations. Germany had more than 2 times the implant rate
of all other nations except Switzerland and 14 times the
implant rate of Ireland and Portugal. Regional variation in
the adoption of medical technology is not unique to TAVR.
In Europe, disparate use of drug-eluting stents and implant-
able cardioverter-deﬁbrillators (ICDs) has previously been
described (5,14,15). The identiﬁcation of inequitable access
to medical technologies is important because it generates
discussion and initiatives to address inequalities and the cor-
responding impact on patient outcomes through payer- and
physician-led programs (e.g., Stent for Life initiative [16]).
Explanations for the divergence in TAVR adoption among
countries are numerous and varied. The economic challenge
of providing progressive care for an aging population has
mandated that the use of new medical device technologies be
not only determined by the expectation of improved clinical
outcomes but also by cost effectiveness. It is axiomatic,
therefore, that the magnitude of healthcare resources inﬂu-
ences the adoption of new medical device technology.
Consistent with our ﬁndings that healthcare expenditure
correlated with TAVR use, the use of ICDs in Europe has
also been associated with national economic performance
(5,14). Not surprisingly, the lowest TAVR implantation rates
were found in Spain, Portugal, and Ireland, who are currently
experiencing substantial economic hardship. In these nations,
the medical device industry could provide additional support
to develop and maintain TAVR programs. As was the case
with drug-eluting stents and ICDs, the introduction of
competitive TAVR systems should decrease procedural costs
and consequently increase TAVR adoption.
Procedural reimbursement and healthcare funding are
critical factors in determining the adoption of new medical
device technology. Previously, these factors were shown to
inﬂuence the use of ICDs and coronary stents. In the current
study, TAVR use and the number of TAVR implants per
AB
Figure 4 TAVR Penetration in Europe
(A) Estimated TAVR penetration among the 11 study nations from 2007 to 2011.
(B) TAVR penetration in each nation in 2011. Broken line represents weighted
average. Abbreviation as in Figure 1.
Table 4 Economic Indexes and Reimbursement Schemes
Volume Indexed GDP
per Capita (PPP)
Healthcare Spend,
% of GDP
Healthc
Capita, 2
Germany 120 11.6
France 107 11.6
Italy 101 9.3
United Kingdom 108 9.6
Spain 99 9.6
the Netherlands 131 12.0
Switzerland 151 11.5
Belgium 118 10.5
Portugal 77 10.7
Denmark 125 11.1
Ireland 127 9.2
Values are actual numbers.
DRG ¼ diagnosis-related group; GDP ¼ gross domestic product; PPP ¼ purchasing power parity; othe
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216center were found to be higher in the presence of nationwide
TAVR-speciﬁc reimbursement schemes than restrictive
reimbursement schemes. The impact of restrictive reim-
bursement systems was evident in the United Kingdom,
Spain, the Netherlands, Belgium, Portugal, and Ireland. We
also observed a trend toward increased TAVR use in nations
in which social insurance rather than taxation was the
principal source of healthcare funding (p ¼ 0.056).
Our estimates of TAVR penetration suggest that TAVR
remains underutilized in Western Europe. Although the
TAVR penetration rate in 2011 was >30% in Germany and
Switzerland, the weighted average penetration among the
11 nations studied was 17.9%, and penetration rates were
<15% in two-thirds of countries. The adoption of new
technology can be a slow process. It requires a threshold of
robust clinical evidence, device iteration, physician training,
and clinical and ﬁnancial planning. Moreover, the cultural
change required to embrace new therapies often evolves
gradually. Given the therapeutic beneﬁt associated with
TAVR in inoperable patients (number needed to treat ¼ 5)
(1), the demonstrable cost effectiveness in both excessive and
high-risk cohorts (17–19), and the less invasive nature of
TAVR procedures, the protracted uptake of TAVR tech-
nology may have negative consequences for patients, physi-
cians, and administrators. Although TAVR penetration is not
necessarily a surrogate for quality of medical care, it may
suggest the need for enhanced patient access to novel and
potentially life-saving therapies. Indeed, it is interesting to
speculate that in nations with higher TAVR penetration rates,
a move toward treating patients at less extreme surgical risk
may be emerging (20).
The impressive clinical trial outcomes with TAVR are
attributable, in part, to the participation of experienced
physicians and institutions. These outcomes are not neces-
sarily reproducible in lower-volume settings (21–23). For
these reasons, volume-based guidelines for catheter-based
and surgical procedures exist (24,25). The recommended
centralization of TAVR procedures in high-volume tertiary
referral centers aims to ensure adequate operator and centerare Spend per
010, US$ (PPP)
Principle Source of
Healthcare Funding TAVR Reimbursement
4,338 Social insurance National TAVR DRG
3,974 Taxation National TAVR DRG
2,964 Taxation Region dependent
3,433 Taxation Cost borne by local trust
3,056 Taxation Cost borne by hospital
5,056 Social insurance Cost borne by hospital
5,270 Social insurance National TAVR DRG
3,969 Social insurance Cost borne by hospital
2,728 Taxation National SAVR DRG.; remainder
of cost borne by hospital
4,464 Taxation National TAVR DRG
3,718 Taxation Cost borne by hospital
r abbreviations as in Tables 1 and 3.
A B
C D
E F
Figure 5 Factors Inﬂuencing TAVR Adoption in Europe
Correlation between TAVR implants per million population (age 75 years) and (A) volume-indexed gross domestic product (GDP); (B) healthcare expenditure (% of GDP); and
(C) annual healthcare spend per capita (U.S.$). Number of TAVR implants per million population (age 75 years) according to (D) the principal source of healthcare funding
(social insurance or taxation) and (E) the system of reimbursement (TAVR speciﬁc or constrained). (F) The average number of TAVR implants per center in 2011 and the system
of reimbursement. DRG ¼ diagnosis-related group; PPS ¼ purchasing power standards; other abbreviation as in Figure 1.
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217volume for these complex procedures (26–28). National
health technology assessments and position papers have
suggested that each center perform a minimum of 24 TAVR
procedures per annum (27,29,30). We observed centers with
low procedural volume and therefore nonadherence to these
criteria in several nations. In particular, centers in Ireland,
Belgium, and Spain performed on average less than 20
implants in 2011. Two distinct observations explain the low
procedural volume: 1) low number of TAVR implants per
million population (Ireland); and 2) excessive number ofTAVR centers (Belgium and Spain). The reasons for the
variation in the number of TAVR centers per million pop-
ulation and center volume across nations are unclear.
National political and ﬁnancial concerns, healthcare policy,
population density and proﬁle, reimbursement strategy, and
cultural factors may be important in determining the number
of centers in each nation.
The way complex medical technology is disseminated has
been revolutionized by TAVR. Clinical site selection,
mandatory physician and team training, and detailed
Figure 6
Reimbursement Systems and TAVR Penetration
Across Europe
Map of the 11 study nations depicting estimated TAVR penetration rate and the
2011 TAVR reimbursement systems. SAVR ¼ surgical aortic valve replacement;
other abbreviations as in Figures 1 and 5.
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standard of care. Nevertheless, the variation in the adoption
of TAVR in Western Europe is clear. Physicians, medical
societies, the medical device industry, and other stakeholders
have a responsibility to ensure the appropriate use and
sensible dispersion of this innovative technology.
Study limitations. Several limitations are of note. First,
although every attempt was made to ensure the validity of
the implant data, both data sources should be considered to
be estimates. Registry data may underestimate the true scale
of TAVR use because some cases or small implant centers
may not have been included. Secondly, the estimates of
TAVR use are likely to have included patients treated for off-
label indications, such as patients at lower surgical risk, which
may have affected the estimates of TAVR penetration.
Conclusions
Despite the rapid adoption of TAVR across Europe, our
ﬁndings indicate that a sizeable treatment gap remains for
high/prohibitive surgical risk patients with severe aortic
stenosis. National economic indexes and reimbursement
strategies are closely linked with TAVR use and may explain
the inequitable adoption of TAVR across nations.
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